Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Dec 1993; 92(6): 2653–2659.
PMCID: PMC288462

Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.


Solute-free water diuretics (aquaretics) by antagonizing hydrosmotic vasopressin receptors (V2) may be useful in treating water-retaining diseases. The effects of intravenous administration of a newly developed nonpeptide, selective V2 antagonist, OPC-31260, at doses ranging from 0.017 to 1.0 mg/kg to groups of healthy, normally hydrated men were compared with those of 0.33 mg/kg furosemide and placebo. OPC-31260 increased the hypotonic urine volume dose dependently for the first 4 h, while furosemide induced sodium diuresis for 2 h. The absolute increase in the cumulative response in the urine to the highest doses of OPC-31260 was not significantly different from that to furosemide. The higher doses of OPC-31260 rapidly lowered urine osmolality for 2 h, particularly between minutes 15 and 45 (e.g., 1.0-mg/kg dose: 63 +/- 2 mOsm/kg in urine collected between minutes 30 and 45). In a marked hypotonic diuresis, mean free water clearance of the 4-h urine increased dose proportionally into the positive range, reaching 1.80 +/- 0.21 ml/min at 1.0 mg/kg. Whereas furosemide induced marked Na and K diuresis, OPC-31260 increased urinary Na excretion only slightly. At 4 h, 0.75 and 1.0 mg/kg of OPC-31260 almost doubled the plasma arginine vasopressin; and the higher doses increased plasma osmolality and plasma Na slightly, but did not alter plasma K, blood pressure, or heart rate. OPC-31260 thus safely induced a potent aquaretic effect in men.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Goldsmith SR, Francis GS, Cowley AW, Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983 Jun;1(6):1385–1390. [PubMed]
  • Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981 Jul 30;305(5):263–266. [PubMed]
  • Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 1982 Apr;96(4):413–417. [PubMed]
  • Brooks DP, Koster PF, Albrightson-Winslow CR, Stassen FL, Huffman WF, Kinter LB. SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta). J Pharmacol Exp Ther. 1988 Apr;245(1):211–215. [PubMed]
  • Hofbauer KG, Mah SC, Opperman JR. Chronic blockade of vasopressin receptors in rats. J Cardiovasc Pharmacol. 1986;8 (Suppl 7):S56–S60. [PubMed]
  • Kinter LB, Churchill S, Stassen FL, Moore M, Huffman W. Vasopressin antagonism in the squirrel monkey (Saimiri sciureus). J Pharmacol Exp Ther. 1987 Jun;241(3):797–803. [PubMed]
  • Stassen FL, Erickson RW, Huffman WF, Stefankiewicz J, Sulat L, Wiebelhaus VD. Molecular mechanisms of novel antidiuretic antagonists: analysis of the effects on vasopressin binding and adenylate cyclase activation in animal and human kidney. J Pharmacol Exp Ther. 1982 Oct;223(1):50–54. [PubMed]
  • Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992 Apr;105(4):787–791. [PMC free article] [PubMed]
  • Manning M, Przybylski JP, Olma A, Klis WA, Kruszynski M, Wo NC, Pelton GH, Sawyer WH. No requirements of cyclic conformation of antagonists in binding to vasopressin receptors. Nature. 329(6142):839–840. [PubMed]
  • Manning M, Sawyer WH. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med. 1989 Dec;114(6):617–632. [PubMed]
  • Brooks DP, Koster PF, Albrightson CR, Huffman WF, Moore ML, Stassen FL, Schmidt DB, Kinter LB. Vasopressin receptor antagonism in rhesus monkey and man: stereochemical requirements. Eur J Pharmacol. 1989 Jan 24;160(1):159–162. [PubMed]
  • Huffman WF, Albrightson-Winslow C, Brickson B, Bryan HG, Caldwell N, Dytko G, Eggleston DS, Kinter LB, Moore ML, Newlander KA, et al. A minor modification of residue 1 in potent vasopressin antagonists dramatically reduces agonist activity. J Med Chem. 1989 Apr;32(4):880–884. [PubMed]
  • Thibonnier M. Vasopressin agonists and antagonists. Horm Res. 1990;34(3-4):124–128. [PubMed]
  • Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M, Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991 Apr 26;252(5005):572–574. [PubMed]
  • Ohnishi A, Ko Y, Fujihara H, Miyamoto G, Okada K, Odomi M. Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans. J Clin Pharmacol. 1993 Mar;33(3):230–238. [PubMed]
  • Albrightson-Winslow CR, Caldwell N, Brooks DP, Huffman WF, Stassen FL, Kinter LB. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs. J Pharmacol Exp Ther. 1989 May;249(2):366–371. [PubMed]
  • Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest. 1973 Sep;52(9):2340–2352. [PMC free article] [PubMed]
  • Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int. 1976 Jul;10(1):25–37. [PubMed]
  • Sladek CD, Blair ML, Ramsay DJ. Further studies on the role of angiotensin in the osmotic control of vasopressin release by the organ-cultured rat hypothalamo-neurohypophyseal system. Endocrinology. 1982 Aug;111(2):599–607. [PubMed]
  • Padfield PL, Morton JJ. Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man. J Endocrinol. 1977 Aug;74(2):251–259. [PubMed]
  • Reif MC, Troutman SL, Schafer JA. Sodium transport by rat cortical collecting tubule. Effects of vasopressin and desoxycorticosterone. J Clin Invest. 1986 Apr;77(4):1291–1298. [PMC free article] [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...